Glutamatergic changes with treatment in attention deficit hyperactivity disorder: A preliminary case series

Journal of Child and Adolescent Psychopharmacology

Volumn 12, Issue 4, 2002, Pages 331-336

  Carrey, Normand ^a,b   MacMaster, Frank P ^a   Sparkes, Sandra J ^a   Khan, Shakeela C ^a   Kusumakar, Vivek ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b IWK HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CREATINE; GLUTAMIC ACID; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; ATTENTION DEFICIT DISORDER; CASE REPORT; CHILD; CORPUS STRIATUM; FEMALE; HUMAN; MALE; NEUROCHEMISTRY; NON INVASIVE MEASUREMENT; PREFRONTAL CORTEX; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOPHARMACOLOGY;

ANTIDEPRESSIVE AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CREATININE; FEMALE; GLUTAMIC ACID; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METHYLPHENIDATE; NEOSTRIATUM; PREFRONTAL CORTEX; PROPYLAMINES; PSYCHIATRIC STATUS RATING SCALES;

EID: 0345505742     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454602762599871     Document Type: Article

References (15)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington (DC), American Psychiatric Association, 1994.
2. Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, Yurgelun-Todd DA, Renshaw PF: Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry 51:493-497, 2002.
3. Groves P, Garcia Munoz M, Linder J, Manley M, Martone M, Young S: Elements of intrinsic organization and information processing in the neostriatum. In: Models of Information Processing in the Basal Ganglia. Edited by Houk J, Davis J, Beiser D. Cambridge (Massachusetts), MIT Press, 1995.
4. Guy W: ECDEU Assessment Manual for Psychopharmacology, rev. Bethesda (Maryland), US Department of Health, Education, and Welfare, 1976, pp. 31-96.
5. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 108:E83, 2001.
6. Orvaschel H, Puig-Antich J: Schedule for Affective Disorders and Schizophrenia for School-Age Children: Epidemiological Version. Fort Lauderdale (Florida), Nova University, Center for Psychological Study, 1994.
7. Pliszka SR, McCracken JT, Mass JW: Catecholamines in attention-deficit hyperactivity disorder: Current perspectives. J Am Acad Child Adolesc Psychiatry 35:264-272, 1996.
8. Rosenberg DR, Keshavan MS: A.E. Bennett Research Award. Toward a neurodevelopmental model of obsessive-compulsive disorder. Biol Psychiatry 43:623-640, 1998.
9. Rosenberg DR, MacMaster FP, Keshavan MS, Dimond K, Stewart C, Moore GJ: Striatal glutamate and treatment response in pediatric obsessive-compulsive disorder. J Am Acad Child and Adoles Psych 39:1096-1103, 2000.
10. Shulman RG: Functional imaging studies: Linking mind and basic neuroscience. Am J Psychiatry 158:11-20, 2001.
11. Solanto MV: Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: A review and integration. Behav Brain Res 94:127-152, 1998.
12. Taber MT, Fibiger HC: Electrical stimulation of the medial prefrontal cortex increases dopamine release in the striatum. Neuropsychopharmacology 9:271-275, 1993.
13. Taber MT, Fibiger HC: Electrical stimulation of the prefrontal cortex increases dopamine release in the nucleus accumbens of the rat: Modulation by metabotropic glutamate receptors. J Neurosci 15:3896-3904, 1995.
14. Verma A, Moghaddam B: Regulation of striatal dopamine release by metabotropic glutamate receptors. Synapse 28:220-226, 1998.
15. Vitiello B: Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder. CMAJ 165:1505-1506, 2001.